U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H15N3.C4H4O4
Molecular Weight 329.3505
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of QUIPAZINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.C1CN(CCN1)C2=CC=C3C=CC=CC3=N2

InChI

InChIKey=QYJJDHZHSCTBII-BTJKTKAUSA-N
InChI=1S/C13H15N3.C4H4O4/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16;5-3(6)1-2-4(7)8/h1-6,14H,7-10H2;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C13H15N3
Molecular Weight 213.2783
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Quizapine is a piperazine-based nonselective serotonin (5-HT) receptor agonist with antidepressant and oxytocic activities. Quipazine targets and binds to serotonin receptors, particularly to the 5HT2A and 5HT3 receptors. Quipazine is a potential anti-parkinsonian agent. Serotonin receptor activation by quipazine may lead to smooth muscle contraction and antidepressant effects. quipazine, a central serotonergic agent, counteracted some of the drug-induced symptoms of pseudoparkinsonism in laboratory animals. Cholinergic, dopaminergic and histaminergic receptors play an important role in the manifestations of these symptoms.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.07 null [pKi]
6.89 null [pKi]
7.27 null [pKi]
1.0 nM [EC50]
Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Facilitation of postural limb reflexes with epidural stimulation in spinal rabbits.
2010-02
A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants.
2010-01
Morphofunctional study of injured spinal cord of rats after activation of serotonergic receptors and motor load.
2009-12-10
Effects of serotonergic agents on survival and hemolymph composition of the larval mosquito Aedes aegypti (Diptera: Culicidae, L.) in vivo: does serotonin regulate hemolymph acid-base homeostasis?
2009-11
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
2009-10-23
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
2009-10
Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.
2009-08-13
Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.
2009-06-11
Serotonin receptor agonist quipazine promotes proliferation and apoptosis of human hepatocyte strain of L-02 strain.
2009-06
Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents.
2009-06
Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
2008-12-01
Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection.
2008-12
Synthesis and biological evaluation of one novel technetium-99m-labeled nitroquipazine derivative as an imaging agent for serotonin transporter.
2008-12
Quantification of deficits in lateral paw positioning after spinal cord injury in dogs.
2008-11-25
Anxiolytics may promote locomotor function recovery in spinal cord injury patients.
2008-08
Effect of intrathecal administration of serotoninergic and noradrenergic drugs on postural performance in rabbits with spinal cord lesions.
2008-08
Facilitation of stepping with epidural stimulation in spinal rats: role of sensory input.
2008-07-30
Step training reinforces specific spinal locomotor circuitry in adult spinal rats.
2008-07-16
Dose dependence of the 5-HT agonist quipazine in facilitating spinal stepping in the rat with epidural stimulation.
2008-06-27
A hydrogen bond in loop A is critical for the binding and function of the 5-HT3 receptor.
2008-06-17
Location and orientation of serotonin receptor 1a agonists in model and complex lipid membranes.
2008-03-21
5-Fluorotryptamine is a partial agonist at 5-HT3 receptors, and reveals that size and electronegativity at the 5 position of tryptamine are critical for efficient receptor function.
2008-02-12
5-HT-receptive structures are localized in the interblastomere cleft of Paracentrotus lividus early embryos.
2008-02
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys.
2008-02
Conservation of structure, signaling and pharmacology between two serotonin receptor subtypes from decapod crustaceans, Panulirus interruptus and Procambarus clarkii.
2008-01
Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats.
2007-12
Epidural spinal cord stimulation plus quipazine administration enable stepping in complete spinal adult rats.
2007-11
[Effect of local microapplication of serotoninergic drugs on membrane currents of Paracentrotus lividus early embryos].
2007-10-06
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 5: 2'-Substituted 6-nitroquipazines.
2007-05-15
Presynaptic modulation of 5-HT release in the rat septal region.
2007-05-11
Behavioral and neuropharmacological evidence that serotonin crosses the blood-brain barrier in Coturnix japonica (Galliformes; Aves).
2007-02
5-HT3 receptor-mediated photic-like responses of the circadian clock in the rat.
2007-02
Implications of assist-as-needed robotic step training after a complete spinal cord injury on intrinsic strategies of motor learning.
2006-10-11
Increased serotonergic functions following adminstration of 1-(1-naphthyl) piperazine in propranolol injected rats.
2006-07
Effect of robotic-assisted treadmill training and chronic quipazine treatment on hindlimb stepping in spinally transected rats.
2006-07
Presynaptic serotonergic modulation of 5-HT and acetylcholine release in the hippocampus and the cortex of 5-HT1B-receptor knockout mice.
2006-06-15
Effects of 5-HT2A receptor stimulation on the discrimination of durations by rats.
2006-02
Spinal cord-transected mice learn to step in response to quipazine treatment and robotic training.
2005-12-14
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
2005-12
Is the platelet serotonin transporter different in venous vs. arterial blood?
2005-11
Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT(1A) receptor.
2005-10
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines.
2005-08-15
N1/P2 component of auditory evoked potential reflect changes of the brain serotonin biosynthesis in rats.
2005-08
Hyperglycemia induced by pharmacological activation of central serotonergic pathways depends on the functional integrity of brain CRH system and 5-HT3 receptors.
2005-08
The serotonergic agonists quipazine, CGS-12066A, and alpha-methylserotonin alter motor activity and induce hindlimb stepping in the intact and spinal rat fetus.
2005-06
Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2.
2005-06
Serotonin-related enhancement of recovery of hind limb motor functions in spinal rats after grafting of embryonic raphe nuclei.
2005-05
Long-lasting recovery of locomotor function in chronic spinal rat following chronic combined pharmacological stimulation of serotonergic receptors with 8-OHDPAT and quipazine.
2005-01-11
Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome.
2005
Involvement of the retinohypothalamic tract in the photic-like effects of the serotonin agonist quipazine in the rat.
2005
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Rats: Quipazine increased serum corticosterone within 30 min after its i.p. injection (at 10 mg/kg) into rats. Elevation of serum corticosterone did not occur with a 1.25 mg/kg dose of quipazine but was dose-related over a 2.5-20 mg/kg dose range.
Route of Administration: Intraperitoneal
In Vitro Use Guide
Quipazine (3.1 x 10(-7)-10(-4) M) caused concentration-dependent contractions of the canine basilar artery.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:48 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:48 GMT 2025
Record UNII
JY444CK9IG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUIPAZINE MALEATE
USAN  
USAN  
Official Name English
MA 1291
Preferred Name English
NSC-758469
Code English
2-(1-Piperazinyl)quinoline maleate (1:1)
Systematic Name English
QUIPAZINE MALEATE [USAN]
Common Name English
MA-1291
Code English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
Code System Code Type Description
CAS
5786-68-5
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID3045190
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
NSC
758469
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
NCI_THESAURUS
C66502
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
ChEMBL
CHEMBL18772
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
FDA UNII
JY444CK9IG
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-314-2
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
SMS_ID
300000055065
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
PUBCHEM
5702242
Created by admin on Mon Mar 31 18:16:48 GMT 2025 , Edited by admin on Mon Mar 31 18:16:48 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY